Most cardiovascular diseases (CVDs), as well as age-related cardiovascular alterations, are accompanied by increases in oxidative stress, usually due to increased generation and/or decreased metabolism of ROS (reactive oxygen species; for example superoxide radicals) and RNS (reactive nitrogen species; for example peroxynitrite). The superoxide anion is generated by several enzymatic reactions, including a variety of NADPH oxidases and uncoupled eNOS (endothelial NO synthase). To relieve the burden caused by this generation of free radicals, which also occurs as part of normal physiological processes, such as mitochondrial respiratory chain activity, mammalian systems have developed endogenous antioxidant enzymes. There is an increased usage of exogenous antioxidants such as vitamins C and E by many patients and the general public, ostensibly in an attempt to supplement intrinsic antioxidant activity. Unfortunately, the results of large-scale trails do not generate much enthusiasm for the continued use of antioxidants to mitigate free-radical-induced changes in the cardiovascular system. In the present paper, we review the clinical use of antioxidants by providing the rationale for their use and describe the outcomes of several large-scale trails that largely display negative outcomes. We also describe the emerging understanding of the detailed regulation of superoxide generation by an uncoupled eNOS and efforts to reverse eNOS uncoupling. SIRT1 (sirtuin 1), which regulates the expression and activity of multiple pro-and anti-oxidant enzymes, could be considered a candidate molecule for a 'molecular switch'.
INTRODUCTION
There is much interest in the role of free radical oxidative damage in human diseases. The first description of free radicals was by Gomberg in 1900 at the University of Michigan; the term free radicals refers to atoms, molecules or ions with unpaired electrons in their outer shells, making them highly reactive in biological systems. This unstable configuration provides energy that is released through reactions with adjacent molecules such as proteins, lipids, carbohydrates and nucleic acids. As a result, oxidative stress is implicated in several human diseases, including hypertension, atherosclerosis and vascular diabetic complications, as well as in the aging process [1] . The majority of free radicals that damage biological systems are oxygen free radicals. Oxygen free radicals or, more generally, ROS (reactive oxygen species), as well as RNS (reactive nitrogen species), are products of normal cellular metabolism [2] . The most common RONS (reactive oxygen and nitrogen species) include O 2 − (superoxide anions), H 2 O 2 (hydrogen peroxide), OH
• (hydroxyl radicals), carboncentred peroxides and peroxyl radicals, NO
• (NO radicals), NO 2 • (nitrogen dioxide radicals), ONOO − (peroxynitrite), ClO − (hypochlorite) and others [3] [4] [5] . O 2 − can be formed from different sources such as xanthine oxidase, NADPH oxidases, uncoupled NOSs (NO synthases), enzymes of the mitochondrial respiratory chain and cytochrome P450 mono-oxygenases [1] . Among these enzymes, NADPH oxidases and uncoupled eNOS (endothelial NOS) are crucial ROS sources under pathological conditions [6] . Oxidative stress defines a state with either increased (uncontrolled) formation of RONS and/or impaired cellular antioxidant defence system (e.g. down-regulation of important antioxidant proteins) with subsequent depletion of low-molecularmass antioxidants and a shift in the cellular redox balance [7] .
Organisms have evolved a number of antioxidant enzymes to combat the burden of increased oxidative stress. An antioxidant refers to any molecule capable of stabilizing or deactivating free radicals before they attach to cells. Humans have evolved highly complex antioxidant systems (enzymatic and non-enzymatic) that work synergistically, and in combination with each other, to protect cells and organ systems of the body against free radical damage. Antioxidants can be either endogenously produced substances or obtained from exogenous sources, e.g. as a part of a diet or as dietary supplements. Some dietary compounds that do not neutralize free radicals, but enhance endogenous activity, can also be classified as antioxidants [8] .
The most efficient enzymatic antioxidants involve GPx (glutathione peroxidase), catalase and SOD (superoxide dismutase) [9] . SOD catalyses the dismutation of O 2 − into H 2 O 2 . There are three isoforms of mammalian SOD:
Cu/Zn-SOD (copper/zinc SOD; SOD1), Mn-SOD (manganese SOD; SOD2) and ec-SOD (extracellular SOD; SOD3). GPx proteins consume reduced glutathione to convert H 2 O 2 into water and lipid peroxides to their respective alcohols, with GPx1 being the most abundant selenoperoxidase and a key antioxidant enzyme in many cell types. Catalase is an intracellular antioxidant enzyme that is mainly located in cellular peroxisomes and to some extent in the cytosol, which catalyses the reaction of H 2 O 2 into water and molecular oxygen [9] . Nonenzymatic antioxidants include vitamins E (tocopherol) and C (ascorbic acid), thiol antioxidants (glutathione, thioredoxin and lipoic acid), melatonin, carotenoids, natural flavonoids and other compounds [10] .
The growing interest in the possible beneficial roles of antioxidant supplements in the treatment of CVD (cardiovascular disease) has contributed to a debate about their value in providing complementary therapies aimed at improving standard therapy. There are numerous explanations for the failure to observe noticeable benefits with the use of currently available antioxidants. It is possible that the agents examined are ineffective and non-specific, and that the dosing regimens and the duration of therapy are insufficient. Vitamins C and E may have pro-oxidant properties with harmful and deleterious interactions. It is also possible that orally administered antioxidants may be inaccessible to the source of free radicals, particularly if ROS are generated in intracellular compartments and organelles. Furthermore, antioxidant vitamins do not scavenge H 2 O 2 , which may be more important than O 2 − in CVD [11] . In the present review, we will discuss strategies for the design of newer antioxidants. For example, it may be more promising to develop antioxidants that accumulate at the site of oxidant formation (e.g. mitochondrial-targeted antioxidants) or to inhibit the sources of oxidants (e.g. NADPH oxidase inhibitors). Another strategy would be the synthetic production of intrinsic antioxidant enzymes (e.g. SODmimetic antioxidants).
OXIDATIVE STRESS IN VASCULAR AGING AND DISEASE
Aging produces complex changes in both structure and function throughout the vascular tree [12] . Mechanisms that underlie vascular homoeostasis and maintain oxygen delivery often become impaired with aging. For example, resting blood flow and most vasodilator responses decline with age. Complex responses including neurovascular coupling and endothelium-dependent regulation of vascular tone exhibit age-related dysfunction in both experimental animals and humans [13] . Vascular or endothelial dysfunction are terms used to describe abnormalities that collectively increase vascular tone, promote thrombosis and alter vascular growth.
Role of oxidative stress
In addition to having direct effects on vascular tone, ROS impair vasodilatory responses mediated by other mechanisms [14] . For example, O 2 − reacts extremely efficiently with NO (the major endothelium-derived relaxing factor) [15] , decreasing the bioavailability of NO. The rate of reaction of superoxide with SOD is 2 × 10 9 M − 1 · s − 1 , while the rate of reaction between NO and superoxide is (6-10) × 10 9 M − 1 · s − 1 , meaning that, when superoxide levels are in excess, NO will preferentially react with superoxide. Since NO plays a major role in vascular biology, loss of normal NO-mediated signalling has broad implications with both short-and long-term consequences [14, 16, 17] . In addition to impairing NO-mediated signalling, the interaction of NO with O 2 − results in formation of ONOO − . Increases in ONOO − occur with age in blood vessels [7] and have several effects including activation of nuclear PARPs [poly(ADP-ribose) polymerases] [18] . Excessive activation of PARP depletes energy stores and thus produces cellular dysfunction [18] . Several studies suggest that activation of PARP contributes to vascular dysfunction with aging [19] . Acute effects of ROS include reductions in resting blood flow and impairment of vasodilator responses. Many chronic effects of ROS also arise, including effects on the ECM (extracellular matrix) and vascular structure via activation of metalloproteinases and other mechanisms.
Other studies have focused on the role of NADPH oxidase in promoting vascular disease [20] . During aging, increased O 2 − occurs in vascular cells and is functionally important, because impaired vascular responses with aging can be restored to normal with scavengers of O 2 − , inhibitors of NADPH oxidase or following genetic deletion of the catalytic subunit of NADPH oxidase [20] . Thus a key source of O 2 − in blood vessels during aging is NADPH oxidase (Figure 1 ).
RAS (renin-angiotensin system)
The RAS plays important roles in vascular biology and is implicated in a variety of pathophysiological conditions including hypertension [14] . Most of the detrimental effects of this system are mediated by AngII (angiotensin II) acting on AT 1 receptors (AngII type 1 receptors). One of the major effects of AngII within vascular cells is AT 1 receptor-dependent activation of pathways that promote oxidative stress. In addition, these receptors activate components of the inflammatory response that contribute to vascular disease as well [14] (Figure 1) .
Studies have focused on the impact of AngII in vascular aging [21] . Expression of the enzyme that produces AngII [ACE (angiotensin-converting enzyme)], tissue levels of AngII and AT 1 receptors all increase with age in blood vessels [22] . Chronic inhibition of the RAS or genetic deletion of AT 1 receptors suppress ONOO − formation and inhibit vascular growth during aging [23] . Both oxidative stress and inflammation play a major role in producing changes that occur within vascular cells which ultimately lead to increased vascular tone, the onset and progression of atherosclerosis, reduced blood flow and increased risk for cardiovascular events. Nox, NADPH oxidase; NF-κB, nuclear factor κB; AT1-R, AT 1 receptor.
Activation of these receptors is functionally important because oxidative stress and endothelial dysfunction does not occur in old animals lacking AT 1 receptors compared to age-matched controls [19] . Such findings provide direct evidence for a fundamental role for AngII and AT 1 receptors in age-related vascular dysfunction [19] . In this regard, it is noteworthy that AngII is a major stimulus for activation of NAPDH oxidase [21] , implicated previously in promoting oxidative stress during aging [7] .
Antioxidants and vascular aging
Studies utilizing mice genetically deficient in individual forms of SOD have implicated key roles for these enzymes in protecting the vasculature during aging. For example, increases in vascular O 2 − with age are augmented in mice partially deficient in SOD1 [heterozygous KO (knockout) mice] [24] . Endothelial function is markedly impaired in old SOD1-deficient mice at an age when these responses are still normal in wild-type mice [24] . Thus oxidative stress and vascular dysfunction with aging is accelerated in the face of SOD1 deficiency. Similarly, SOD2 haploinsufficiency increases oxidative stress and augments endothelial dysfunction with aging [25] .
Klotho is a gene known to inhibit age-related symptoms and extend life span [26] . In relation to vascular disease, klotho suppresses pro-oxidant mechanisms including AngII-induced O 2 − formation in endothelial cells [27] . In a genetic model of spontaneous hypertension, overexpression of klotho reduces the expression and activity of NADPH oxidase and O 2 − levels in the vasculature [28] . Although potentially important, the functional importance of klotho within the vessel wall during normal aging has not been defined.
Possible therapies for vascular aging have emerged recently [13] . For example, voluntary exercise decreases oxidative stress and improves endothelial function in old mice [29] . These beneficial effects appear to result from a combination of increased SOD activity and reduced expression of NADPH oxidase [29] . Short-term caloric restriction also reduces oxidative stress and enhances vascular function during aging [30] . Such findings are important because they provide evidence that vascular dysfunction with age is not entirely fixed and may be reversed or lessened with appropriate treatment or intervention.
PPAR (peroxisome-proliferator-activated receptor) γ
PPARγ is a ligand-activated transcription factor active in vascular cells [31] , where it regulates expression of multiple target genes including genes that promote or suppress increases in ROS. Antioxidant effects of PPARγ occur in blood vessels. For example, genetic interference to decrease the expression of PPARγ in adult mice increases vascular O 2 − and impairs vascular function, as well as producing hypertrophy and inward remodelling in the microcirculation [32] . Activators of PPARγ prevent vascular remodelling during hypertension, decrease expression of AT 1 receptors and NADPH oxidase, while increasing the expression of SOD1 [31] ( Figure 1 ).
There is an emerging appreciation of a role for PPARγ in aging, with the findings that the expression and activity of PPARγ decreases with age [33] and that decreases in PPARγ expression reduce lifespan in mice [34] . Expression of klotho increases following pharmacological activation of PPARγ [35] and thus may contribute to the protective effects of PPARγ [34] . In heterozygous KO mice expressing a human dominantnegative mutation in the ligand-binding domain of PPARγ (which inhibits transcriptional activity of wildtype PPARγ ), age-related vascular dysfunction occurred earlier and to a greater extent compared with age-matched controls. Oxidative stress appears to underlie this accelerated age-induced vascular dysfunction, because a scavenger of O 2 − prevented these changes. These preliminary findings suggest a fundamental role for PPARγ in protection against age-induced oxidative stress and vascular dysfunction. Consistent with these results, vascular dysfunction in an aged model of Alzheimer's disease improves in response to a synthetic activator of PPARγ [36] .
THERAPEUTIC USE OF ANTIOXIDANTS IN CVD
Evidence for a beneficial effect of antioxidants such as vitamin C on cardiovascular events is based on observations that patients with a pronounced improvement of endothelial function (measured by acetylcholine-induced forearm dilation) in response to vitamin C infusion were at higher risk for cardiovascular events as compared with those patients displaying only minor improvement of endothelial function in response to vitamin C infusion [37] . The main conclusion of this study was that patients with increased vascular oxidative stress (making them more responsive to vitamin C) displayed a higher incidence of cardiovascular events. In addition, molecular proof for the involvement of oxidative stress in cardiovascular complications is based on animal experimental models with genetic deletion of NADPH oxidase subunits or of antioxidant enzymes. Related to this, only two examples are mentioned. In mice with MI (myocardial infarction), the genetic deletion of the NADPH oxidase subunit p47 phox almost normalized vascular NO • bioavailability, reduced ROS formation and improved heart function, as well as the survival rate by 20 % after MI [38] . In contrast, deletion of mitochondrial SOD increased agedependent mitochondrial oxidative stress and endothelial dysfunction [39] . Some animal experimental models for CVDs that are associated with oxidative stress are shown in Figure 2 . Given the importance of oxidative stress in almost all cardiovascular, inflammatory and neurodegenerative diseases, pharmacological control of the sources of oxidative stress may be of great clinical interest. However, considering the fact that some RONS have important functions in immune defence and fulfil functions in redox signalling, this therapeutic strategy requires cautious fine tuning and spatial selectivity.
Clinical trials of antioxidants in CVD
In patients with or at higher risk of CVD, there is both basic science and clinical trial evidence for an improvement in atherosclerosis with statins [40] , niacin [41] , fibrates [42] , aspirin, n − 3 fatty acids [43] and a Mediterranean diet [44] . Unfortunately, such dual evidence does not exist for antioxidants. Despite very promising basic science findings [45] , the clinical trial results with various antioxidants have been disappointing and the possible reasons for the divergent results are reviewed below.
Clinical trial evidence
β-Carotene (60-200 mg, daily) was studied in 138 113 subjects in four large primary and four large secondary prevention trials [46] . Six trials individually showed no benefit and two trials individually showed increased mortality. A meta-analysis showed a significant increase in total mortality (absolute risk increase 0.4 %, P = 0.003). Vitamin E (300-800 units, daily) was studied in 81 788 subjects in two large primary and five large secondary prevention trials [46] . No trial individually showed an effect on mortality. A meta-analysis showed no effect on total mortality (absolute risk increase 0.2 %, P < 0.42). One secondary prevention trial [CHAOS (Cambridge Heart Antioxidant Study)] showed a significant reduction in MI (absolute risk decrease 2.6 %, P = 0.01); however, meta-analysis of all of the trials revealed no effect on MI (absolute risk unchanged, P = 0.93).
Probucol (500 mg, daily) was studied in 246 subjects in FAST (Fukuoka Atherosclerosis Trial) [47] . Probucol reduced carotid initimal medial thickness and decreased the combined end point of cardiovascular death, MI and revascularization (P < 0.05). However, in PQRST (Probucol Quantitative Regression Swedish Trial) with 276 subjects, probucol (500 mg) did not slow the progression of femoral intimal medial thickness [48] . Probucol was removed from the market because it increased the QTc interval.
Succinobucol (300 mg, daily) was studied in 6144 subjects in the ARISE (Aggressive Reduction of Inflammation Stops Events) trial [49] . There was no effect on the primary end point of cardiovascular death, cardiac arrest, MI, stroke, angina or revascularization (P = 0.96). In this trial, there were divergent effects on the end points: succinobucol significantly reduced cardiovascular death, cardiac arrest, MI and stroke (P = 0.03), while significantly increasing angina and revascularization. It is important to note that succinobucol was not marketed. A combination of vitamin E (600 mg), vitamin C (250 mg) and β-carotene (20 mg) in the Heart Protection Trial (20 536 subjects) had no significant effect on mortality, MI or stroke [50] .
The Mediterranean diet used in the Lyon trial [44] showed a very large 5.2 % first year and large 1.6 % subsequent year absolute risk reduction in MI and cardiovascular death [51] . This occurred despite a relatively small reduction in LDL (low-density liporotein)-cholesterol from 176 to 162 mg/dl. Some of this reduction in MI and cardiovascular death may have resulted from the change in diet from saturated and n − 6 fats to n − 3 and n − 9 fats [44] . However, it is also possible that antioxidants present in the Mediterranean diet also had some effect on MI and cardiovascular death. Further clinical trials on the effect of antioxidants in the Mediterranean diet are indicated.
Some potential explanations for negative clinical trials
It is possible that the antioxidant doses used in these clinical trials may have been inadequate. Roberts et al. [52] found that a daily dose of 1600 or 3200 mg of vitamin E (RRR-α-tocopherol) in humans was required to induce significant reductions in plasma F 2 isoprostanes. This suggests that the doses of vitamin E (300-800 mg) used in the clinical trials described above may have been insufficient. In addition, the following are also possible. (i) Some antioxidant preparations are more protective than others, for example α-compared with γ -tocopherol.
(ii) Antioxidant therapy may be beneficial in the early phases of atherosclerosis, although arguing against this hypothesis is the lack of benefit in the primary prevention trials described above. (iii) Endogenous antioxidants are more important than exogenous antioxidants. For example, Collins et al. [53] found that LDLR (LDL receptor)
− / − mice fed on a high-fat diet had more aortic atherosclerosis, more oxidative stress (higher plasma F 2a isoprostane and higher vascular O 2 − ) and lower levels of endogenous antioxidants [lower SOD, catalase, GPx-1, GPx-4, NADPH dehydrogenase quinone 1 and upstream mediators of antioxidants including FOXO (forkhead box O) 1 and FOXO4]. It is possible that the increase in atherosclerosis observed in these mice could have resulted from decreased levels of endogenous antioxidants. (iv) The route of administration of antioxidants is important. Oral administration could potentially allow oxidation by gastrointestinal bacteria, a process that could limit antioxidant benefits. The effects of oral oxidants can be quite complex. For example, coffee drinking in humans increased urinary oxidant H 2 O 2 3-10-fold; incubation of coffee in a neutral medium also generates 120-420 μM H 2 O 2 [54] . Theoretically, these findings would suggest that coffee drinking should be pro-oxidant and therefore harmful; however, meta-analyses show no effect of coffee intake on CVD [54] and may indeed have a protective effect on dementia [55] . A possible scenario is that administration of a mild pro-oxidant could induce endogenous antioxidant production, which is cardio-and vasculo-protective.
These findings suggest that we do not have data supporting oral administration of single or combination antioxidant supplements at present. However, they do not rule out a benefit from antioxidants in food given the large benefits observed with a Mediterranean diet, which includes both food-based antioxidants, high ω − 3 and ω − 9 fatty acids, and low ω − 6 and saturated fats.
Antioxidant treatment: oral compared with infusion, and chronic compared with acute
As noted above, large clinical trials with antioxidants such as vitamins C and E did not show any benefit for oral antioxidant treatment on the incidence and prognosis of CVDs. In contrast, the first controlled studies such as HOPE (Heart Outcome Prevention Evaluation) and HOPE-TOO (Heart Outcome Prevention EvaluationThe Ongoing Outcomes), as well as a prospective study with vitamin C in post-menopausal women with diabetes mellitus, reported an increased incidence of cardiomyopathy, left heart decompensation and cardiovascular mortality in the group with antioxidant treatment [56] . These large-scale trials with oral treatment are in contrast with a great number of animal experimental studies [57] , as well as human studies with rather small numbers of patients and acute infusion of antioxidants [58] , indicating that antioxidants may be highly beneficial in improving endothelial dysfunction. The main reasons for the failure of chronic oral antioxidant therapy could be as follows: vitamins C and E act as pro-oxidants, the CAD (coronary artery disease) of the patients included is already irreversible, the CAD patients are already being treated with drugs displaying antioxidant properties [for example ACE inhibitors and ARBs (angiotensin receptor blockers)], chronic antioxidant therapy inhibits intrinsic ischaemic preconditioning, which relies on RONS formation, or oral vitamin treatment does not result in high enough concentrations of the antioxidants at the place of oxidative stress. Some of these reasons would favour the acute infusion of vitamin C in accordance with respective observations.
Direct RONS scavengers
Vitamin C reacts with free radical species (for example OH
• ) in two subsequent one-electron-oxidation steps, yielding ascorbyl radicals as an intermediate that either undergo disproportionation to ascorbic acid and dehydroascorbate or are reduced by glutathione. The two-electron oxidation product dehydroascorbate is reduced (restored) by dehydroascorbate reductase. It is important to note that these classical antioxidants would be depleted without an associated reduction system. Other important examples of this class are vitamin E, thiol-based compounds (for example glutathione and cysteine), thioethers (for example methionine), bilirubin and many more. In the presence of OH
• , almost any biomolecule may act as an antioxidant. The other class of classical antioxidants acts catalytically and comprises enzymes with a metal centre or selenocysteine: SODs that catalyse the breakdown of O 2 − , catalases to detoxify H 2 O 2 and GPxs to scavenge H 2 O 2 , ONOO − and lipid peroxides. These considerations already indicate the requirements for a synthetic antioxidant: if it is consumed during the antioxidant reaction, it should use a cellular reduction system in order to be restored. A catalytically acting synthetic antioxidant seems even more promising.
Another question is which kind of oxidant should be scavenged by the synthetic antioxidant. Since ascorbic acid and tocopherol are poor scavengers of O 2 − , the structure of a synthetic O 2 − scavenger should be different. The reactivity of a RONS may change upon protonation: O 2 − are much less reactive as compared with HOO
• (hydroperoxyl radicals), which show a considerable reaction rate with ascorbic acid, tocopherol and unsaturated fatty acids. ONOO − is rather unreactive, whereas its conjugated acid (ONOOH) or its CO 2 adduct (ONOOCO 2 − ) or, more precisely, the free radicals derived during their decomposition display high reactivity towards a broad range of biomolecules. Accordingly, each of these species requires specially designed antioxidants. For example, to inhibit the nitration of tyrosine by ONOOH, ascorbic acid or uric acid is more efficient compared with glutathione or methionine, since they specifically react with ONOOHderived free radicals (up to 30 % based on the ONOOH concentration) which mediate nitration. Glutathione and methionine react with the ONOO − until they are consumed and the remaining ONOO − undergoes protonation with subsequent radical-mediated nitration of tyrosine. This results in low IC 50 values for ascorbic acid and uric acid and high IC 50 values for glutathione and methionine. In contrast, prevention of ONOO − -mediated oxidation of the zinc-sulfur active site of alcohol dehydrogenase is conferred by low IC 50 values for glutathione and methionine, whereas ascorbic acid and uric acid require high concentrations to show any effect, and vitamin C even had some pro-oxidative effects in this system. These considerations have been reviewed elsewhere [59, 60] .
Some promising synthetic antioxidants used previously were mimetics of antioxidant enzymes. Ebselen [2-phenyl-1,2-benzoisoselenazol-3(2H)-one] was designed as a GPx mimetic to scavenge H 2 O 2 and lipid peroxides [61] . This compound was among the fastest reacting synthetic ONOO − scavengers. The therapeutic indication of ebselen was in the field of transplantation surgery and was intended to prevent ischaemia/reperfusion damage to transplanted organs. Unfortunately, ebselen displayed severe liver toxicity, which could have been related to its high reactivity with all thiols (for example ebselen is a potent inhibitor of alcohol dehydrogenase and other thiol-dependent enzymes) [62] . Another group of synthetic antioxidants comprise the soluble metal pophyrins {FeTMPyP [iron (III) tetrakis(N-methyl-4 -pyridyl)porphyrin], FeTMPS [iron(III) meso-tetra(2,4,6-trimethyl-3,5-disulfonato)porphyrin chloride] and MnT-BAP [Mn(III)tetrakis(4-benzoic acid)porphyrin]} acting as SOD mimetics [63] , whose development and preclinical tests were spearheaded by the pharmaceutical company Monsanto [64] . Although these compounds are clearly catalytic and display high reaction rates with O 2 − and ONOO − , they never reached clinical utility, most probably due to their toxicity when used at higher concentrations or possibly because they can also be prooxidant under some conditions (for example by acting as a catalyst of phenol nitration) [59] .
Inhibitors of RONS sources
It may be more promising to inhibit the formation of RONS instead of scavenging these harmful species after their emergence. Controlling mitochondrial RONS formation will be addressed later in the present review. Inhibition of xanthine oxidase is a well-recognized strategy to improve cardiovascular complications in several CADs, as supported by animal experimental studies using allopurinol or tungsten treatment [65] , as well as clinical studies in patients with Type 2 diabetes and idiopathic dilated cardiomyopathy [66] . Most published data on the beneficial effects of xanthine oxidase inhibition are related to ischaemia/reperfusion damage after MI [67] .
Another therapeutic target of interest is the NADPH oxidases, since their involvement in most CVDs has been demonstrated sufficiently in the literature [68] . These multi-protein complexes are of special pharmacological interest, since there are many regulatory pathways and accordingly many sites for pharmacological intervention. The following inhibitory mechanisms apply for the phagocytic NADPH oxidase isoform (Nox2, gp91 phox ): apocynin or more precisely its peroxidase-activated dimer inhibits the assembly of NADPH oxidase [69] , the PKC (protein kinase C) inhibitor chelerythrine blocks phosphorylation and translocation of the cytosolic p47 phox subunit, gliotoxin and PAO (phenyl arsenoxide) target essential thiol groups at the site of assembly of cytosolic subunits and thereby suppress activation, the third-generation β-blocker nebivolol interferes with the assembly but even may dislocate already assembled cytosolic subunits, and DPI (diphenyliodonium) inhibits the electron flow in NADPH oxidases (as it does in all flavin-dependent oxidoreductases) and inhibits O 2 − formation. All of these NADPH oxidase inhibitors have been demonstrated to be highly efficient in animal models of CVD, but to date have not been not employed in patients due to their toxicity, with the exception of the β-blocker nebivolol, which has yet to be tested for its effects on NADPH oxidase in patients. There are more than 20 registered patents for NADPH oxidase inhibition in the U.S. Patent Collection database, and there is a great effort to develop (isoform-) specific NADPH oxidase inhibitors [70] . As studies suggest the important roles for O 2 − and H 2 O 2 in cellular signalling, proliferation, migration and differentiation [71] , all therapeutic strategies to inhibit NADPH oxidases (Nox1, Nox2 and Nox4) require cautious and tedious evaluation in cell culture and animal models.
Another source of RONS formation may be an uncoupled NOS. Under certain conditions, for example depletion of the cofactor BH 4 (tetrahydrobiopterin), oxidation of the zinc-sulfur complex at the dimerbinding site, excess of ADMA (asymmetric ω-N G ,N Gdimethylarginine), S-glutathionylation of eNOS and adverse (PKC-dependent) phosphorylation at Thr 495 , the function of NOS can transform from an NO-to a O 2 − -producing enzyme [72] . There is ample evidence for a contribution of eNOS-dependent O 2 − formation and a loss of NO synthesis due to cardiovascular complications [72] . One therapeutic option for eNOS 'recoupling' is supplementation with BH 4 or its precursors sepiapterin and folic acid, which are cheaper and more stable. Supplementation with BH 4 has proven highly beneficial on endothelial function in many studies, such as improvement in diabetic patients or chronic smokers [73] . Overexpression or activity enhancement of GCH (GTP cyclohydrolase) represents another pathway to increase BH 4 levels as demonstrated in diabetic mice [74] . Under certain conditions, the levels of ADMA are increased in endothelial cells, which may contribute to the uncoupling of eNOS, and supplementation with a high dose of l-arginine may be of great benefit by replacing ADMA or even support its export from endothelial cells by driving the cationic amino acid transporters. This may be of clinical importance since ADMA is a valid predictor of cardiovascular events and is associated with increased cardiovascular mortality [75] . Besides these directly eNOS-targeting therapeutic interventions, any cardiovascular therapy that reduces oxidative stress will contribute to 'recoupling' of eNOS, as demonstrated for ACE inhibition, ARB therapy, treatment with statins or antihyperglycaemic drugs and, to a lesser extent, treatment with calcium antagonists or β-blockers [76] .
Mitochondria-targeted antioxidants or 'fixing a hole'
Mitochondria are important sources of oxidative stress, especially O 2 − formation. This was documented by the lethality of MnSOD deletion, the mitochondrial SOD [77] , whereas mice with a deficiency in extracellular Cu/Zn-SOD survived [78] . Previous and recent findings have suggested that mitochondrial RONS are involved in many cardiovascular complications (for example in the setting of diabetes, hypertension and MI) and may even act as amplifiers of cytosolic oxidative stress, and thus inducing vicious cycles of RONS-mediated effects [79] . The hypothesis behind this amplification mechanism is that mitochondrial RONS engages in cross-talk with cytosolic RONS sources (and vice versa) by mechanisms involving mitochondrial channels, such as the mPTP (mitochondrial permeability transition pore) and mtK ATP channels (mitochondrial ATP-sensitive potassium channels). Therefore one strategy to control mitochondrial RONS formation could be 'fixing a hole', as suggested by Di Lisa and Bernardi [80] . There are great opportunities for the pharmacological manipulation of these mitochondrial channels, which have so far been somewhat disregarded by the pharmaceutical industry. A study by Piot et al. [81] has demonstrated a significant reduction in MI-induced cardiac damage in patients receiving a post-infarct infusion of the mPTP blocker cyclosporin A [81] . Numerous studies indicate a beneficial effect of mPTP blockade to reduce oxidative damage in response to ischaemia/reperfusion, and that inhibition of the mtK ATP channel may thus represent an attractive therapeutic target, since drugs such as glibenclamide or 5-hydroxydecanoate have beneficial effects in many CAD-related models. However, errant manipulation of this susceptible system may have disastrous outcomes, since these mitochondrial channels are not only important gates for cellular compounds, but are also intimately involved in ischaemic preconditioning, a process that is believed to have essential implications for priming the cell for future (oxidative) stress events and increasing their adaptation to altered redox conditions. Another option to suppress mitochondrial RONS formation is to target antioxidants to the mitochondria. There are numerous examples of this strategy, but one of the first successes was with using mitoQ (mitoquinone) [82] , a quinone that is coupled to a triphenylphosphonium group to facilitate mitoQ accumulation in mitochondria by up to 10 000-fold. GTN (nitroglycerine)-induced vascular dysfunction was improved by inhibition of mtK ATP channels or the mPTP [83] , and MnSOD deletion aggravated the adverse effects of GTN on vascular function and oxidative stress [84] , whereas another study reports that GTN induced oxidative stress and nitrate tolerance was normalized by mitoQ [85] . Previous findings have suggested that mitoTEMPO is another highly effective drug able to suppress mitochondrial RONS formation and stop cellular vicious cycles of RONS generation. MitoTEMPO was able to completely normalize AngIIinduced endothelial dysfunction and increase in blood pressure in mice [86] . Overexpression of MnSOD showed similar protective effects under these conditions.
Endothelium-targeted antioxidants
Administration of extracellular SOD, which directly binds to the endothelium, is highly protective in many CVD states [87] . Likewise, deletion of extracellular SOD impairs vascular function and haemodynamics [87] . Therefore the targeting of extracellular SOD to the endothelium is a promising strategy to prevent endothelial (vascular) dysfunction. Shuvaev et al. [88] have demonstrated that targeting of SOD, but not catalase, to the endothelium reversed AngII-induced endothelial dysfunction. The antioxidant enzymes SOD and catalase were conjugated with an antibody against PECAM-1 (platelet/endothelial cell adhesion molecule-1) to ensure endothelial binding. The results of that study demonstrate that O 2 − is a more harmful species in the vascular system than H 2 O 2 .
The coupling of heparin to 4-amino-TEMPO to create a spin-labelled amide of heparin has been used to study the heparin-anti-thrombin complex [89] . This strategy appears to be highly attractive, since the endothelium has heparin-binding sites. In addition, most synthetic or biological low-or high-molecular-mass molecules can be conjugated to heparin. Moreover, heparin is easier to use compared with, for example, an antibody. Despite these advantages, to the best of our knowledge, there are no industry-based targeted approaches using this rationale, with only modest interest by academic researchers to pursue this hypothesis and create new heparin-bound antioxidants.
Cardiovascular drugs with pleiotropic antioxidant effects
Many cardiovascular drugs (for example ACE inhibitors, ARBs and statins) have pleiotropic antioxidant properties; as such they cause decreases in NADPH oxidase activity and a 'recoupling' of eNOS. Hydralazine and PETN (pentaerithrityl tetranitrate) are two examples of drugs that are regarded as rather antiquarian, but are now recognized to have additional properties that can be exploited for therapeutic benefits. Hydralazine was one of the first antihypertensive drugs used, but is now mainly used for treating pre-eclampsia. However, it experienced a 'revival' when the company NitroMed introduced their combination drug BiDil containing hydralazine and isosorbide dinitrate. This combination therapy showed an impressive decrease in mortality in Afro-Americans with severe heart failure and who responded poorly to ACE inhibitors and other standard medication (the study design was based on data from V-HeFT (VasodilatorHeart Failure Trial) and A-HeFT (African-American Heart Failure Trial) [90] . We can only speculate as to why the combination of hydralazine and isosorbide dinitrate has beneficial effects, but previous findings indicate that hydralazine is a highly efficient RONS scavenger [91] , which in part contributes to the improvement in GTN-induced nitrate tolerance [92] and may thus also beneficially influence isosorbide-5-mononitrate-induced endothelial dysfunction [93] .
Another interesting example of a cardiovascular drug with pleiotropic antioxidant effects is PETN. After it was developed in the U.S.A., it was abandoned, but then used for many years in the former East Germany. After the reunion of Germany, PETN use seized the nitrate market and is now the best selling nitrate in Germany. PETN is the only organic nitrate in clinical use that is devoid of nitrate tolerance and endothelial dysfunction [94] . On the basis of earlier studies, PETN is a potent inducer of the intrinsic antioxidant HO-1 (haem oxygenase-1) system [95] and extracellular SOD [96] . Even more surprisingly, a gene array study has revealed that PETN, in contrast with GTN, induces a number of cardioprotective genes, whereas GTN induces cardiotoxic genes [97] . Although both compounds are organic nitrates and regarded as NO donors, they have distinctly different gene regulation profiles, indicating that organic nitrates are not a homogenous class of drugs [98] . Recent findings suggest that PETN also improves vascular complications in an animal model of Type 1 diabetes mellitus [98a] .
ANTIOXIDANTS AND EPCs (ENDOTHELIAL PROGENITOR CELLS)
EPCs have been described as a circulating CD34-positive cell population derived from bone marrow and homing to sites of ischaemia where they exert their effects on endothelial repair and angiogenesis by various means: (i) EPCs directly integrate into blood vessels and physically participate in endothelial repair [99] , (ii) EPCs deliver angiogenic growth factors to ischaemic tissues and contribute to angiogenesis via paracrine effects [100] , and (iii) EPCs also release MMPs (matrix metalloproteinases) to promote a concomitant increase in matrix degradation that enables endothelial cell migration and vascular remodelling [101] (Figure 3) . The past 12 years has provided growing evidence in support of EPC-based cell therapy as a promising strategy to restore deficient endothelial function and angiogenesis in CVDs [102] . However, several clinical trials have revealed that reduced EPC number is associated with diabetes mellitus [103] , hypertension [104] , aging [105] and hypercholesterolaemia [103] , in which EPCs are continuously exposed to ROS. EPCs from diabetic, hypertensive and aged patients (and also from animal models) exhibit impaired proliferation, adhesion and incorporation into vascular structures [106] . In addition, EPC senescence is positively correlated with the severity of hypertension and reduced telomerase activity [107] . The alterations of EPC biology in diseased conditions
Figure 3 Schematic diagram of EPC mobilization and participation in angiogenesis
EPCs are derived from bone marrow, spleen, adipose tissue and liver. Mobilized EPCs circulate in peripheral blood as specific heterogeneous population co-expressing stem cell markers (CD133 and CD34) and endothelial cell markers [CD31, vWF (won willebrand factor) and VE-cadherin]. EPCs can home to ischaemic sites, where they participate in angiogenesis in several patterns. (a) EPCs directly integrate into blood vessels and physically anticipate endothelium repair. (b) EPCs deliver angiogenic growth factors to ischaemic tissues and contribute to angiogenesis by paracrine effects. EPCs secrete the angiogenic growth factors VEGF, IGF (insulin-like growth factor), FGF (fibroblast growth factor) and GM-CSFs (granulocyte/macrophage colony-stimulating factors). The insoluble factors recruit circulating endothelial cells, fibroblasts and macrophages to ischaemic sites promoting angiogenesis and tissue repair in injured sites. (c) EPCs also release MMPs, such as MMP-2 and MMP-9, to promote a concomitant increase in matrix degradation that enables endothelial cell migration and vascular remodelling. EC, endothelial cell. raise significant concerns about its clinical applications. Reduced EPC pro-angiogenic ability associated with cardiovascular risks, including diabetes, hypertension and age, limits their therapeutic applications in these patients. Furthermore, the relatively low level of circulating EPCs and their finite proliferative potential limits their expansion to sufficient numbers for some therapeutic applications. Thus understanding the pathogenic role of oxidative stress in EPC dysfunction will identify potential targets to improve the efficiency of EPC therapy in CVDs.
Normal EPCs, compared with mature endothelial cells, are more resistant to oxidative stress due to their intrinsically high expression of intracellular antioxidant enzymes (such as catalase, Mn-SOD and GPx-1), which facilitate their active participation in repair at ischaemic sites [108] . Thus inhibition of these enzymes results in abundant ROS accumulation in EPCs, and leads to EPC apoptosis and impaired migration [109] . However, there are several CVD-related risk factors, such as hyperglycaemia, hyperlipidaemia, AngII and AGEs (advanced glycation end-products), which can also significantly augment intracellular ROS accumulation and thus lead to poor hindlimb blood reperfusion and decreased Matrigel plug tube formation [110] . Compelling evidence indicates that EPC dysfunction may be one possible reason for impaired angiogenesis and subsequent vasculopathies in diabetes, hypertension and aged subjects [111] . It has been reported that EPCs exhibit increased apoptosis and diminished tube-forming ability ex vivo and in vivo in response to oxidative stress, which was directly linked to the activation of a redox-dependent Ask1 (apoptosis signal-regulating kinase 1) [111] . This leads to the speculation that ROS accumulation exceeds the intrinsic antioxidant capacity of EPCs and/or that the antioxidant defences of EPCs are damaged under these diseased conditions, consequently retarding angiogenesis. NADPH oxidase is a major ROS generator in vascular systems and its activation plays an important role in EPC senescence through elevating oxidative stress and inactivating telomerase in AngII-treated EPCs [107] .
eNOS uncoupling is another well-known pathogenic process impairing EPC mobilization, which is associated with increased intracellular ROS generation [112] . It has been demonstrated that eNOS critically regulates EPC mobilization and function, but is uncoupled in saltsensitive hypertension because of the reduced availability of the cofactor BH 4 [113] . Overexpression of GCH1, the rate-limiting enzyme of BH 4 de novo synthesis, protects EPC function in salt-sensitive hypertensive rats, partially via suppressing TSP-1 (thrombospondin-1; a potent angiogenesis inhibitor) secretion and oxidative stress [113] . In addition, accumulating evidence shows that levels of antioxidant enzymes are diminished in vascular diseases. For example, Mn-SOD levels are significantly decreased in EPCs in both Type 1 and Type 2 diabetes, which can be restored by activation of AMPK (AMPactivated protein kinase) [114] . Other studies report that p66
ShcA , a subunit of the adaptor protein ShcA, modulates oxidative stress and survival of EPCs in response to high glucose through inhibiting Mn-SOD expression [115] . Levels of the normally abundant antioxidant enzyme GPx-1 are decreased in aged EPCs [116] , whereas CRP (C-reactive protein; a marker of CAD) promotes EPC sensitivity towards oxidant-mediated apoptosis and telomerase inactivation through diminished GPx-1 activity [117] . Taken together, these findings suggest that enhanced ROS generation and impaired antioxidant capacity contributes to excessive ROS accumulation in EPCs, damaging endogenous EPC function and resulting in poor endothelial repair and angiogenesis (Figure 4) .
Interventions that inhibit excessive ROS generation or restore antioxidant capacity in EPCs could potentially improve the outcomes of EPC therapy in clinical applications. Several strategies have been developed to improve the homing, survival and therapeutic potential of EPCs and these are aimed at counteracting EPC dysfunction. Some strategies attempt to systemically stimulate endogenous EPC mobilization and improve their function. Physical exercise is an important non-pharmacological intervention to increase EPC mobilization [118] , and PPARγ agonists (for example piaglitazone) increase the number and migration of EPCs in patients with CAD and abnormal glucose tolerance by reducing NADPH oxidase activity [119] . Systemic administration of UAG (unacylated ghrelin) prevented diabetes-induced EPC damage (by modulating the NADPH oxidase regulatory protein Rac1) and also improved the angiogenic potential in patients with Type 2 diabetes and in diabetic mice [120] . In addition, UAG facilitates the recovery of bone marrow EPC mobilization by rescuing eNOS activity [120] . Some studies have used factors such as SDF-1 (stromal-cell-derived factor-1), VEGF (vascular endothelial growth factor) and SHH (Sonic hedgehog) to recruit EPCs from the bone marrow to the peripheral blood, thereby leading to the formation of new vessels at ischaemic sites [102] . Other potential strategies involve the ex vivo manipulation of impaired EPCs before autologous cell therapy. For example, restoration of Mn-SOD activity in diabetic EPCs by ex vivo Mn-SOD gene transfer successfully improves their therapeutic efficiency in diabetic wound healing [121] . Constitutive hTERT (human telomerase reverse transcriptase) transduction protects EPCs from ROS-induced senescence and improves their tubeforming ability [122] . Pre-treatment of EPCs with an eNOS enhancer, which significantly up-regulates eNOS expression in EPCs, enhances the therapeutic effects of cell therapy [123] . Of note is a recent study reporting that suppressing SIRT1 (sirtuin 1) rescued mir-34a-induced EPC senescence [124] , indicating that microRNAs may present a novel therapeutic target for enhancing the regenerative capacity of EPCs. Thus strategies protecting EPCs from excessive oxidative stress would ensure that they maintained their highly proliferative and angiogenic potential in ischaemic sites.
There is emerging a clear appreciation that oxidative stress impairs EPC function and mobilization in a number of vascular diseases. The evidence from basic and clinical research provides the basis for the development of novel targeting to regulate the redox status of EPCs and improve their utilization in treating vascular diseases. Currently, findings on the utility of EPCs are derived from animal models or small-scale clinical trials. Significant advances will be derived from multi-centre clinical trials aimed at further evaluating EPC therapy in revascularization in various vascular diseases.
REDUCING CARDIOVASCULAR OXIDATIVE STRESS BY TARGETING SIRT1
Reducing ROS formation (by down-regulating ROSproducing enzymes) and enhancing ROS inactivation (by up-regulating the endogenous antioxidant systems) should be more effective than using non-specific antioxidant scavengers to ameliorate oxidative stress. The optimal approach would be to modulate the expression or activity of multiple redox genes by targeting a single molecule, analogous to a 'master switch'. It is not yet known whether such a 'master switch' exists, but there is intriguing evidence that the class III histone deacetylase SIRT1 modulates several endogenous pro-and antioxidative enzymes concurrently and could thus be a candidate molecule.
SIRT1 catalyses the NAD + -dependent deacetylation of ε-amino-acetylated lysine residues from protein substrates [125] . It regulates a variety of cellular functions, such as genome maintenance, longevity and metabolism [126] . SIRT1 has been implicated as a key mediator of the pathways downstream of calorie restriction, a dietary regimen shown to extend the lifespan of many species, including yeast, worms, flies, mice, dogs and rhesus monkeys. Humans on long-term calorie restriction have lower levels of inflammation, show fewer signs of cardiovascular aging and better memory performance. SIRT1 protein levels in several tissues are increased following calorie restriction [125] .
SIRT1 has also emerged as a promising new therapeutic target to treat Type 2 diabetes [125] . SIRT1 activators improve insulin sensitivity, increase mitochondrial content and prolong the survival of mice fed a high-fat high-calorie diet. A potent and selective SIRT1 activator, SRT1720, improves glucose homoeostasis, increases insulin sensitivity in the liver, skeletal muscle and fat, and increases mitochondrial function in rodent models of Type 2 diabetes. Importantly, transgenic overexpression of SIRT1 in mice recapitulates many of the findings produced by pharmacological activation of SIRT1 [127] . Moreover, SIRT1 is probably also a novel target in preventing atherosclerosis. TIMP3 (tissue inhibitor of metalloproteinases 3) levels are reduced in atherosclerotic plaques from subjects with Type 2 diabetes and are increased by SIRT1 [128] . SIRT1 down-regulates AT 1 receptor expression in vascular smooth muscle cells [129] . Endothelium-specific overexpression of SIRT1 decreases atherosclerosis in ApoE (apolipoprotein E)-KO mice [130] . There is evidence that SIRT1 also modulates cardiovascular oxidative stress. Moderate overexpression of SIRT1 (up to 7.5-fold) enhances the expression of catalase and protects the heart from oxidative stress induced by paraquat [131] . A very high level of SIRT1 (12.5-fold), however, increases apoptosis/fibrosis and stimulates cardiomyopathy. The latter may be due to mitochondrial dysfunction and NAD + depletion [131] . SIRT1 is a key regulator of oxidative stress in the cardiovascular system by targeting multiple redox genes simultaneously. Under a number of pathological conditions, the enzymatic reduction of molecular oxygen by eNOS is no longer coupled to l-arginine oxidation, resulting in the production of O 2 − rather than NO. This phenomenon is referred to as eNOS uncoupling (see above) [132] . Evidence for eNOS uncoupling has been obtained in animal models of CVD, as well as in patients with endothelial dysfunction resulting from hypercholesterolaemia, diabetes mellitus or essential hypertension, and in chronic smokers [76] .
The hypercholesterolaemic atherosclerosis-prone ApoE-KO mice can be used as a model of oxidative stress and eNOS uncoupling. The major cause of eNOS uncoupling is a deficiency of the essential eNOS cofactor BH 4 due to oxidative-stress-mediated oxidation of the molecule. BH 4 supplementation is capable of correcting eNOS dysfunction in several types of pathophysiology [76] . Untreated ApoE-KO mice show increased oxidative degradation of BH 4 [133] and significant ROS production in their aortas [133] and hearts [134] . Both aortic [133] and cardiac [134] O 2 − production can be reduced by the NOS inhibitor l-NAME (N G -nitro-l-arginine methyl ester), indicating that eNOS is in an uncoupled state and that it produces ROS in this pathological model. BH 4 is synthesized from GTP via a de novo pathway, with GCH1 acting as the rate-limiting enzyme. Treatment of ApoE-KO mice with the SIRT1 activator resveratrol results in enhanced expression of GCH1 and elevated levels of BH 4 [134] . At the same time, cardiac O 2 − production in resveratrol-treated mice is markedly reduced to a level that cannot be lowered any further by l-NAME. These data suggest that eNOS is no longer producing O 2 − in resveratrol-treated ApoE-KO mice, i.e. resveratrol can reverse eNOS uncoupling [134] . Resveratrol has both SIRT1-dependent andindependent effects. The up-regulation of GCH1 by resveratrol is probably mediated by SIRT1 as this effect can be reduced by the SIRT1 inhibitor sirtinol or by siRNA (small interfering RNA)-mediated SIRT1 knockdown [134] .
Treatment of ApoE-KO mice with resveratrol also causes a significant down-regulation of Nox2 and Nox4 in cardiac tissue [134] . Similar effects are also observed in cultured endothelial cells. Nox4 is the most predominant Nox isoform in human EA.hy 926 endothelial cells [135] . Treatment of these cells with resveratrol results in a dose-dependent down-regulation of Nox4 [135] . siRNAmediated knockdown of SIRT1 has no effect on the Nox4 down-regulation by resveratrol, indicating that the effects of resveratrol on Nox4 is SIRT1-independent.
Resveratrol enhances the expression of all three SOD isoforms, GPx1 and catalase in both ApoE-KO mice and cultured human EA.hy 926 endothelial cells [134] . Inhibition of SIRT1 with sirtinol or knockdown of SIRT1 reduces the effects of resveratrol on SOD1, SOD2 and GPx1, but not that of SOD3 or catalase in EA.hy 926 endothelial cells [134] . These results indicate that the effects of resveratrol on SOD1, SOD2 and GPx1 are SIRT1-dependent, whereas its effects on the SOD3 and catalase are probably SIRT1-independent in this cell type. In contrast with these results obtained in human EA.hy 926 endothelial cells, SIRT1 overexpression has been shown to induce catalase in cardiac tissues [131] . The SIRT1-dependent up-regulation of antioxidant enzymes also occurs in cardiovascular tissues in other disease models. TO-2 hamsters have a genetic defect in the δ-sarcoglycan gene and spontaneously develop dilated cardiomyopathy. Oral treatment of TO-2 hamsters with the SIRT1 activator resveratrol increases SOD2 levels in cardiomyocytes, suppresses fibrosis, preserves cardiac function and significantly improves survival. In C2C12 myoblasts, the up-regulation of SOD2 by resveratrol depends on the level of nuclear SIRT1. siRNAs against SOD2 or SIRT1 [136] can block the cell-protective effects of resveratrol. Thus SIRT1 appears to act as a molecular switch able to modulate oxidative stress in the cardiovascular system ( Figure 5 ). It prevents O 2 − production from uncoupled eNOS and enhances ROS detoxification by SOD1, SOD2, GPx1 and catalase.
Given the pivotal role of oxidative stress in pathology, SIRT1 is a promising target for the development of new drugs to treat CVDs. Figure 6 provides a summary of the oxidant mechanisms that contribute to vascular dysfunction. Possible antioxidant therapeutic interventions are also provided within the scheme. Despite the fact that most large clinical trials do not support a beneficial role of oral antioxidant therapy for CVDs, there is ample evidence that antioxidant therapy may be protective when directed to specific sites and administrated acutely. In addition, some of the most promising therapeutic targets have not been exploited thus far (e.g. mitochondrial pores or NADPH oxidases), and there is a poor recognition of the pleiotropic antioxidant properties of established drugs. In addition to the strategies aimed at developing new synthetic therapeutics that have been reviewed, there is also the possibility of gene therapy with microRNAs and antagomirs, which will undoubtedly create exciting new avenues for future strategies for antioxidant therapy, for example by silencing of oxidant-producing systems or inducing antioxidant systems.
OUTLOOK AND CLINICAL IMPLICATIONS

CONCLUSIONS
Despite extensive basic science evidence for the benefit of antioxidants, clinical trials show little benefit from oral antioxidant supplements. We have reviewed details of the clinical trials and have discussed possible reasons that oral antioxidant supplements have been ineffective as either preventative or therapeutic agents in CVDs. Vascular dysfunction routinely occurs with aging. Activation of AT 1 receptors by local or circulating AngII appears to be a key element for activation of pathways that increase the production of ROS and promote oxidative stress. Protective molecules within vascular cells, including SOD1, SOD2, and PPARγ , may function normally to suppress vascular aging. An emerging area of importance is the negative role of oxidative stress in the functioning and mobilization of EPCs. Thus increasing the intrinsic antioxidant activities of EPCs would bode well in the ongoing efforts to repair the damaged intimal lining of blood vessels in diabetes, hypertension etc. It is likely that targeting the sources that generate free radicals, such as uncoupled eNOS, will make great strides. An additional approach would be the modulation of SIRT1, which can be considered a molecular switch that is able to inhibit O 2 − production from uncoupled eNOS, while also augmenting free radical metabolism by intracellular enzymes.
